SG Americas Securities LLC Acquires 12,578 Shares of Precigen, Inc. (NASDAQ:PGEN)

SG Americas Securities LLC lifted its holdings in shares of Precigen, Inc. (NASDAQ:PGEN) by 27.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,641 shares of the biotechnology company’s stock after purchasing an additional 12,578 shares during the period. SG Americas Securities LLC’s holdings in Precigen were worth $65,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Iridian Asset Management LLC CT raised its stake in Precigen by 82.5% during the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after buying an additional 1,706,815 shares during the period. Geode Capital Management LLC raised its stake in shares of Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after purchasing an additional 149,829 shares during the last quarter. State Street Corp raised its stake in shares of Precigen by 1.0% in the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after purchasing an additional 29,253 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Precigen by 11.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after purchasing an additional 127,467 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Precigen by 26.4% in the third quarter. FMR LLC now owns 345,204 shares of the biotechnology company’s stock worth $327,000 after purchasing an additional 72,033 shares during the last quarter. Institutional investors own 33.51% of the company’s stock.

Analyst Ratings Changes

PGEN has been the subject of several analyst reports. JMP Securities reissued a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a research note on Tuesday, January 14th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price (up from $4.00) on shares of Precigen in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Precigen has an average rating of “Hold” and an average target price of $7.00.

Precigen Stock Up 3.7 %

PGEN stock opened at $1.98 on Friday. The firm has a market cap of $579.88 million, a PE ratio of -3.60 and a beta of 1.66. The business has a 50 day moving average of $1.13 and a 200-day moving average of $1.04. Precigen, Inc. has a 12-month low of $0.65 and a 12-month high of $2.04.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.